Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials
- 1 January 1997
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 11 (1), 65-71
- https://doi.org/10.1177/026988119701100116
Abstract
This study evaluates the relative effectiveness and side-effects of risperidone as compared with conventional neuroleptics in the treatment of schizophrenia, by meta-analysis of 11 double-blind, randomized controlled trials. The proportion of patients showing clinical improvement; use of medications for extrapyramidal side- effects (EPS); the treatment drop-out rates; and the changes in negative PANSS scores were measured. Compared with conventional neuroleptics, slightly more patients in the risperidone group showed clinical improvement [57 vs 52%; odds ratio 1.27, 95% confidence interval (CI): 1.04, 1.56]. The use of concomitant medications for EPS was significantly less in the risperidone group than in the conventional neuroleptic group (22.8 vs 38.4%; odds ratio 0.51, 95% CI: 0.41, 0.63). The overall drop-out rate was lower in the risperidone group than in other neuroleptic group (29.1 vs 33.9%; odds ratio 0.75, 95% CI: 0.61, 0.94). The difference in changes in negative PANSS score between the risperidone and the haloperidol group was —0.74 (95% CI: -1.50, 0.02). Weight gain and tachycardia are more common in patients treated with risperidone. Sensitivity analysis of different analytic approaches did not materially change the main estimates. It was concluded that the short- term efficacy of risperidone is comparable to other neuroleptics in the treatment of schizophrenia. It is associated with significantly fewer EPS than conventional neuroleptics (mainly haloperidol).Keywords
This publication has 29 references indexed in Scilit:
- Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus HaloperidolThe British Journal of Psychiatry, 1995
- Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double‐blind parallel‐group trialActa Psychiatrica Scandinavica, 1995
- A Risk-Benefit Assessment of Risperidone in SchizophreniaDrug Safety, 1995
- RisperidoneThe Lancet, 1994
- The New Atypical AntipsychoticsThe British Journal of Psychiatry, 1994
- Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbationsActa Psychiatrica Scandinavica, 1993
- Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double‐blind comparative studyActa Psychiatrica Scandinavica, 1992
- Can meta-analyses be trusted?The Lancet, 1991
- A general parametric approach to the meta‐analysis of randomized clinical trialsStatistics in Medicine, 1991
- Antipsychotic DrugsDrugs, 1977